Kiniksa Pharmaceuticals International (KNSA) Other financing activities (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Other financing activities for 9 consecutive years, with $17.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other financing activities rose 37.92% year-over-year to $17.6 million; the trailing twelve-month figure through Jun 2026 stood at $48.8 million (up 73.98% YoY), and the FY2025 full-year result was $40.8 million, up 136.25% from the prior year.
• Other financing activities rose to $17.6 million in Q2 2026 per KNSA's latest filing, from $6.4 million in the prior quarter.
• Across five years, Other financing activities topped out at $17.6 million in Q2 2026 and bottomed at $510000.0 in Q1 2023.
• Historically, Other financing activities has averaged $4.9 million across 5 years, with a median of $2.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Other financing activities plunged 78.77% in 2022, then jumped 1022.91% in 2025.
• Over 5 years, Other financing activities stood at $1.3 million in 2022, then declined by 25.81% to $957000.0 in 2023, then jumped by 184.22% to $2.7 million in 2024, then jumped by 215.29% to $8.6 million in 2025, then soared by 104.97% to $17.6 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $17.6 million, $6.4 million, and $8.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.